Anivive

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). The name typically refers to just the cancerous versions rather than all such tumours.

FDA Grants Full Approval to Laverdia for Canine Lymphoma

Anivive Lifesciences has received full FDA approval for Laverdia (verdinexor), making it the first FDA-approved oral, at-home treatment for canine lymphoma and converting the drug’s previous conditional approval to full approval.

Anivive’s Oral Lymphoma Drug Laverdia-CA1 Receives FDA Conditional Approval for Dogs

The FDA has conditionally approved Anivive’s Laverdia-CA1 (verdinexor), the first oral SINE-based therapy designed for canine lymphoma, expanding at-home treatment options for both B-cell and T-cell disease.

Topics

FDA Grants Full Approval to Laverdia for Canine Lymphoma

Anivive’s Oral Lymphoma Drug Laverdia-CA1 Receives FDA Conditional Approval for Dogs

Tuskegee Adopts ScribbleVet AI Scribe Platform for Clinical Training

Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer

Virbac Reports 7.4% Organic Revenue Growth in First Half of 2026, Confirms Full-Year Outlook

Chewy Tops 2026 Axios Harris Poll as America’s Most Trusted Company

Study Finds Credelio Quattro Demonstrated Faster Tick Kill Than Competing Oral Preventives

CVS Pharmacy Expands Into Veterinary Prescriptions With Nationwide Pet Medication Service